Iet uz pamatdaļu

Sirpjveida šūnu anēmija (bērniem)

Krīzes novēršana

Fetālā hemoglobīna farmakoloģiskā indukcija

Pharmacotherapy in sickle cell disease—state of the art and future prospects. (opens new window)

Hankins J, Aygun B.

Avots‎: Br J Haematol 2009;145(3):296-308.

Raksts indeksēts‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

https://www.ncbi.nlm.nih.gov/pubmed/19222472 (opens new window)

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. (opens new window)

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Avots‎: Blood 2005;106(7):2269-75.

Raksts indeksēts‎: PubMed 16172253

DOI‎: 10.1182/Blood-2004-12-4973

https://www.ncbi.nlm.nih.gov/pubmed/16172253 (opens new window)

Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. (opens new window)

John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE

Avots‎: N Engl J Med 2020;382(26):2524-33.

Raksts indeksēts‎: PubMed 32579813

DOI‎: 10.1056/NEJMoa2000146

https://www.ncbi.nlm.nih.gov/pubmed/32579813 (opens new window)

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. (opens new window)

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Avots‎: Br J Haematol 2013;161(6):852-60.

Raksts indeksēts‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

https://www.ncbi.nlm.nih.gov/pubmed/23590693 (opens new window)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. (opens new window)

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Avots‎: Arch Dis Child 2013;98(11):908-14.

Raksts indeksēts‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

https://www.ncbi.nlm.nih.gov/pubmed/23995076 (opens new window)

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. (opens new window)

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Avots‎: Pediatrics 2008;122(6):1332-42.

Raksts indeksēts‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

https://www.ncbi.nlm.nih.gov/pubmed/19047254 (opens new window)

Impact of hydroxyurea on clinical events in the BABY HUG trial. (opens new window)

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Avots‎: Blood 2012;120(22):4304-10.

Raksts indeksēts‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

https://www.ncbi.nlm.nih.gov/pubmed/22915643 (opens new window)

Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. (opens new window)

Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators

Avots‎: N Engl J Med 2019;380(2):121-31.

Raksts indeksēts‎: PubMed 30501550

DOI‎: 10.1056/NEJMoa1813598

https://www.ncbi.nlm.nih.gov/pubmed/30501550 (opens new window)

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. (opens new window)

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Avots‎: J Pediatr 2002;140(2):225-9.

Raksts indeksēts‎: PubMed 11865275

DOI‎: 10.1067/mpd.2002.121383

https://www.ncbi.nlm.nih.gov/pubmed/11865275 (opens new window)

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. (opens new window)

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Avots‎: Pediatrics 2013;132(4):677-83.

Raksts indeksēts‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

https://www.ncbi.nlm.nih.gov/pubmed/23999955 (opens new window)

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). (opens new window)

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Avots‎: Lancet 2011;377(9778):1663-72.

Raksts indeksēts‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

https://www.ncbi.nlm.nih.gov/pubmed/21571150 (opens new window)

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. (opens new window)

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Avots‎: Lancet 2016;387(10019):661-70.

Raksts indeksēts‎: PubMed 26670617

https://www.ncbi.nlm.nih.gov/pubmed/26670617 (opens new window)

How I use hydroxyurea to treat young patients with sickle cell anemia. (opens new window)

Ware RE.

Avots‎: Blood 2010;115(26):5300-11.

Raksts indeksēts‎: PubMed 20223921

DOI‎: 10.1182/blood-2009-04-146852

https://www.ncbi.nlm.nih.gov/pubmed/20223921 (opens new window)

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. (opens new window)

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Avots‎: Blood 2004;103(6):2039-45.

Raksts indeksēts‎: PubMed 14630791

DOI‎: 10.1182/blood-2003-07-2475

https://www.ncbi.nlm.nih.gov/pubmed/14630791 (opens new window)

Infekciju un citu sarežģījumu novēršana

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (opens new window)

Hirst C, Owusu-Ofori S.

Avots‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Raksts indeksēts‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (opens new window)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (opens new window)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Avots‎: Lancet Haematol 2021;8(5):e323-33.

Raksts indeksēts‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (opens new window)

Sickle cell disease. (opens new window)

Meremikwu MM, Okomo U.

Avots‎: BMJ Clin Evid 2011;02:2402.

Raksts indeksēts‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (opens new window)

A phase 3 trial of l-glutamine in sickle cell disease. (opens new window)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Avots‎: N Engl J Med 2018;379(3):226-35.

Raksts indeksēts‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (opens new window)

Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. (opens new window)

Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo L, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham TS, Ware RE

Avots‎: Blood. 2023 23;141(12):1402-10.

Raksts indeksēts‎: PubMed 36375125

DOI‎: 10.1182/blood.2022017051

https://pubmed.ncbi.nlm.nih.gov/36375125/ (opens new window)

Malaria chemoprophylaxis in sickle cell disease. (opens new window)

Oniyangi O, Omari AA.

Avots‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Raksts indeksēts‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (opens new window)